secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001104659-23-059164
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia Q1 net loss $5.7M; FDA approves Mydcombi for mydriasis
---------------------------------------------------------------

- FDA approved Mydcombi (tropicamide/phenylephrine) for mydriasis, first product using Optejet delivery system.
- Received FDA feedback on Microline presbyopia candidate providing clear and efficient path forward.
- Entered co-development agreement with Formosa Pharmaceuticals to combine Optejet with APNT nanoparticle platform.
- Q1 net loss $5.7M ($0.15/share) vs $7.3M ($0.24/share) in Q1 2022; operating expenses down to $5.5M.
- Cash and equivalents $18.5M at March 31, 2023; additional $5M available on Avenue Capital credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923059164/0001104659-23-059164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923059164/tm2315261d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-059164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer